Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report report published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $65.00 target price on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2024 earnings at ($1.43) EPS, Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

Other analysts have also issued reports about the stock. Royal Bank of Canada initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, March 28th. They issued an outperform rating and a $70.00 price target for the company. TD Cowen started coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an outperform rating on the stock. Oppenheimer reissued an outperform rating and issued a $80.00 target price on shares of Jasper Therapeutics in a report on Thursday, March 7th. Finally, Evercore ISI initiated coverage on shares of Jasper Therapeutics in a research report on Wednesday, April 3rd. They set an outperform rating and a $65.00 price target for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $64.29.

Jasper Therapeutics Stock Up 1.1 %

JSPR stock opened at $21.42 on Monday. The business has a 50 day moving average of $25.52 and a 200 day moving average of $15.12. The firm has a market cap of $322.59 million, a PE ratio of -3.45 and a beta of 2.25. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.65) by $0.15. On average, research analysts expect that Jasper Therapeutics will post -5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors have recently bought and sold shares of JSPR. Fernwood Investment Management LLC boosted its position in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after acquiring an additional 40,000 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Jasper Therapeutics in the 1st quarter valued at about $2,343,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Jasper Therapeutics during the 1st quarter worth approximately $599,000. Kingdon Capital Management L.L.C. raised its position in shares of Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after buying an additional 500,000 shares during the period. Finally, Opaleye Management Inc. acquired a new position in Jasper Therapeutics in the fourth quarter valued at approximately $3,144,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.